Introduction
Dasatinib (BMS-354825, Bristol-Myers Squibb, New York) is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases (SFKs) , that in vitro has demonstrated 325-fold greater potency compared with imatinib mesylate in cells transduced with unmutated BCR-ABL 1 . A recent Phase I dose-escalation study has
shown that dasatinib has considerable activity and an excellent safety profile in the treatment of patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in all disease phases 2 .
CML is a malignant clonal disorder of hematopoietic stem cells that results in increased numbers of myeloid cells, erythroid cells and platelets in the peripheral blood, and myeloid hyperplasia in the bone marrow 3 . It is well established that the expression of a constitutively activated tyrosine kinase, BCR-ABL, which is sufficient to generate the CML phenotype in normal cells 4, 5 , leads to the development of CML in humans. The BCR-ABL fusion gene occurs as a result of a reciprocal translocation between chromosomes 9 and 22, producing the shortened 22q known as the Philadelphia chromosome (Ph) 6 . CML typically progresses via three phases: chronic, accelerated and blast 7 . Definitions of accelerated phase (AP) vary, but the term is typically used to describe patients who show certain signs of disease progression and resistance to therapy, but who do not yet meet the criteria for blast phase 8 . Key features of AP include: significant increases in peripheral blood and bone marrow blasts or basophils, development of extramedullary disease, extremes in platelet levels, increasing drug requirements, unresponsive splenomegaly and persistent fever or bone pain 8, 9 .
While the current mainstay of CML treatment, imatinib, inhibits the BCR-ABL fusion protein, resistance to imatinib represents an important clinical problem, especially in later stages of CML. Forty to fifty percent of patients with accelerated phase CML For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From 5 (CML-AP) were estimated to have developed imatinib resistance after 2 years of treatment; that percentage increased to 75% after 4 years of treatment 10, 11 . In addition to the problem of imatinib resistance, intolerance may be a concern among a small subset of patients. In a Phase II study of imatinib, 4% of CML-AP patients experienced adverse events (AE) so severe that treatment was discontinued 12 .
Treatment options for CML-AP patients who have imatinib-intolerant or -resistant disease are extremely limited. Allogeneic stem cell transplantation is an alternative, but is associated with significant early morbidity and mortality, and is restricted by availability of suitable donors [13] [14] [15] . Therefore, alternative therapies are needed for this patient group.
Resistance to imatinib is frequently associated with BCR-ABL point mutations, the majority of which prevent BCR-ABL from adopting the inactive conformation required for imatinib binding 16 . However, a number of other likely mechanisms of resistance exist, including BCR-ABL amplification and activation of alternative signaling pathways, such as those involving the SFKs [17] [18] [19] [20] [21] [22] . Evidence suggests that these SFKs, functioning downstream and upstream of BCR-ABL and in BCR-ABLindependent pathways, may play a role in the progression of CML to the more aggressive phenotypes of advanced disease [23] [24] [25] . A number of genetic abnormalities have been identified that may be associated with progression from chronic to blast phases, including: duplication of the Ph chromosome, trisomy of chromosome 8 or 19, isochromosome 17(q) and mutations in p53, p16/ARF and Rb
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. A recent microarray study identified a number of progression-associated events, including WNT/β-catenin pathway dysregulation, decreased Jun B and Fos expression, alternative kinase dysregulation and increased PRAME expression 27 .
Dasatinib was rationally designed to comprehensively target the underlying causes of imatinib resistance that have been identified to date [16] [17] [18] [19] [20] [21] [22] . Results are summarized in tabular format for a formal interim analysis conducted with a minimum follow-up of 6 months; a subsequent analysis extending the follow-up to at least 8 months forms the main focus for this present report.
Study design and methodology

Objectives
The primary objective of the study was to determine the major hematologic response (MaHR) and overall hematologic response (OHR) rates to dasatinib in patients with imatinib-resistant CML-AP. Secondary objectives included: the determination of the durability of hematologic responses; the hematologic and cytogenetic response rates;
and the assessment of the safety and tolerability of dasatinib. Baseline mutational analyses were also performed in order to assess responses to dasatinib in the context of specific BCR-ABL mutations.
Patients
Patients were recruited to the study at 40 clinical sites worldwide. 
Study treatment
Following screening, eligible patients received dasatinib 70 mg twice daily (BID) (140 mg total daily dose), based on the previously reported outcome of a Phase I doseescalation study 2 . Treatment with dasatinib continued until progression of disease despite dose escalation or development of intolerable toxicity. Following the last dose of study therapy, all patients were followed for a minimum of 30 days or until recovery from all toxic effects, whichever was longer. Follow-up visits occurred at least every 4 weeks until all study-related toxicities resolved to baseline or National Cancer No treatment for CML other than dasatinib was permitted, with the exception of anagrelide and hydroxyurea (limited to a period of approximately 2 weeks for hydroxyurea) for the treatment of elevated platelet counts (>700,000/mm 3 ) and white blood cell counts (>50,000/mm 3 ), respectively.
Efficacy assessments
Hematologic response
Hematologic responses were determined by assessment of once-weekly complete blood counts (CBC). Hematologic responses were scored as MaHR, minor (MiHR) or no response (Table 1) . A patient with a MaHR was required to meet the criteria for either a CHR or no evidence of leukemia (NEL; see Table 1 ). The OHR was defined as the proportion of the treated population with a best response of MaHR or MiHR.
Confirmed hematologic responses were required to be maintained for a minimum of 
Disease progression
Disease progression in patients who had achieved a MaHR or MiHR was defined as failure to meet the criteria for a MaHR or MiHR, respectively, on all assessments over a consecutive 2-week period after receiving the maximum dose of dasatinib.
Progression was also defined as no decrease from baseline levels in percentage blasts in PB or BM on all assessments over a 4-week period after receiving the maximum dose of dasatinib.
Analysis of BCR-ABL expression and mutational status
Data were collected from exploratory assays, including evaluation of mRNA from PB cells by quantitative PCR, in order to characterize changes in the level of expression of, and analysis of, point mutations in the BCR-ABL gene.
Safety assessments
Safety information was assessed for patients who received at least one dose of dasatinib. Patients were assessed by physical examination, performance status, vital signs and 12-lead electrocardiogram (ECG) at baseline. Adverse events (AE;
hematologic and non-hematologic) were evaluated throughout the study and graded according to the NCI-CTC Version 3.0.
Study conduct
The study was conducted in accordance with the Declaration of Helsinki, and was consistent with International Conference on Harmonization Good Clinical Practice (ICH GCP) and applicable regulatory requirements. Written, informed consent was obtained from every patient prior to clinical trial participation. The protocol was reviewed and approved by a recognized ethics review committee at each trial center.
Statistical analysis
A minimum sample size of 60 treated patients with imatinib-resistant CML was required to give a maximum width of the exact two-sided 95% confidence interval (CI) of 25% when the hematologic response rate was in the expected 5-30% range.
Efficacy analyses were performed for the treated population, which included all patients who received at least one dose of dasatinib. Two-sided 95% exact CIs were calculated for the primary endpoints MaHR and OHR using the Clopper-Pearson method 32 . Duration of hematologic response (overall and complete) was estimated with the Kaplan-Meier product limit method. A two-sided 95% CI for the median duration of hematologic response was calculated using the Brookmeyer and Crowley method 33
. Kaplan-Meier estimates of progression-free survival (PFS) with the 95%
CIs for the median time to progression were determined.
Analysis of all safety and laboratory observations and demographic characteristics were performed descriptively. 
Results
Patients and demographics
Results for the present report include 107 patients who were enrolled into the study between December 2004 and May 2005 and received at least one dose of study medication. Of these patients, 99 had imatinib-resistant CML-AP and eight had CML-AP but could not tolerate imatinib. Reasons for imatinib intolerance included:
gastrointestinal symptoms (n=1); arthralgia/myalgia (n=2); rash (n=1); and other (n=6; other included pancytopenia, thrombocytopenia and neutropenia). Intolerance could result from more than one toxicity symptom.
Demographic characteristics were representative of patients with CML-AP, and were comparable between imatinib-resistant and -intolerant groups ( Table 2 ). The age range in the study population was 23-86 years, with similar proportions of males and females (51% and 49%, respectively). Treated patients had a long history of CML: the median time from initial diagnosis to the start of dosing was approximately 91 months, although this value was markedly lower for patients with imatinib-intolerant CML-AP (69 months) than for patients with imatinib-resistant CML-AP (91 months).
The patients in this study had been extensively pretreated; aside from imatinib, all had previously received other, and in some cases, multiple, therapies for CML, including hydroxyurea or anagrelide (96%), interferon-α (75%), chemotherapy (67%), stem cell transplantation (18%) and radiotherapy (4%). They also had been treated at length and with high doses of imatinib; the majority of patients (68%) had received >3 years of imatinib therapy, and 59% had been treated with doses of imatinib >600 mg/day (Table 2) Table 3 summarizes the hematologic response rate to dasatinib treatment after 6 and 8 months' follow-up.
Of the 69 patients who achieved a MaHR, only 7 patients (all with imatinib-resistant CML-AP) progressed ( Figure 1, Table 3 ).
At 8 months' follow-up, the OHR rate was 81% (87/107) of patients in the total population (CHR 39%; NEL 25%; MiHR 17%). Comparable OHR rates of 81% (80/99) and 88% (7/8) were observed in the imatinib-resistant and imatinib-intolerant CML-AP populations, respectively (Table 3) . Of the 87 patients who achieved an OHR with dasatinib, 15 progressed (13 with imatinib-resistant CML-AP and 2 with imatinib-intolerant CML-AP); median duration of OHR still had not been reached.
Cytogenetic responses were also seen in a notable proportion of patients (Table 4) .
At 8 months' follow-up, MCyR was achieved in 33% of the total treated population
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(CCyR 24%; PCyR 8%), 34% of patients in the imatinib-resistant group (CCyR 25%; PCyR 9%) and 13% of patients in the imatinib-intolerant group (CCyR 13%; PCyR 0%). The median time to achieve MCyR for the total population was 57 days (range 28-263 days) ( Table 4 ). 
Response to dasatinib by baseline BCR-ABL mutational status
Baseline mutational analysis of the ABL kinase domain was available for 100/107 patients in the treated population (94 with imatinib-resistant CML-AP and 6 with imatinib-intolerant CML-AP). Mutations were identified in 60 (60%) of these patients (all with imatinib-resistant CML-AP).
Among the 60 patients with mutations, 26 unique imatinib-resistant mutations were identified, of which G250E was the most common (n=9) ( Table 5) . Of these 60 patients, 30 (50%) carried mutations located within the P-loop of the kinase domain.
Despite the presence of imatinib-resistant BCR-ABL mutations and their association with poor prognosis, at 8 months' follow-up, 73% of patients with an imatinib-resistant BCR-ABL mutation had achieved MaHR following treatment with dasatinib.
Moreover, 73% and 86% of patients with an imatinib-resistant mutation in the kinase P-loop or activation loop, respectively, had achieved MaHR. In addition, MaHR was achieved in 70% of patients with mutations known to confer mild to very high resistance to imatinib. Similarly, MCyR was achieved in 30% of patients with imatinibFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From resistant mutations, 23% of patients with an imatinib-resistant mutation in the kinase P-loop, 57% of patients with an imatinib-resistant mutation in the activation loop and 24% of patients with mutations known to confer mild to very high resistance to imatinib (Table 5) .
Safety
Non-hematologic AE related to treatment that occurred with an incidence of ≥ 10% at 8 months' follow-up are shown in Table 6 . Most non-hematologic AE were mild-tomoderate. The most frequently reported drug-related AE were diarrhea (50%), headache (28%), pyrexia (23%), fatigue (23%), nausea (22%) and peripheral edema (22%). Pleural effusion occurred in 25 (23%) patients; this was grade 3-4 in 3 (3%) patients. Three patients (3/25, 12%) underwent thoracentesis while no patient required pleurodesis. In general, most pleural effusions were uncomplicated, resolving with temporary dose interruption, diuretics, and in some cases, pulse steroids. The most common (≥5%) grade 3-4 non-hematologic AE related to treatment were diarrhea (6%) and gastrointestinal bleeding (7%).
As would be expected in this population of pre-treated patients with CML-AP, a proportion of patients had severe (grade 3-4) pancytopenia at baseline: 5% had severe leukopenia, 7% had severe neutropenia, 23% had severe thrombocytopenia and 5% had severe anemia (Table 2) . Overall, the majority of patients in the safety population had experienced some degree of pancytopenia at 8 months' follow-up (Table 6 ). Cytopenias were reversible and could be managed effectively by dose interruption and/or reduction. Among treated CML-AP patients at 8 months' follow-up, 91 (85%) had received packed red blood cell transfusions (including all 8 imatinibintolerant CML-AP patients) and 65 (61%) had received platelet transfusions. Plasma was administered to 3 (3%) patients. Of the 107 patients treated, 13 (12%) were hospitalized for febrile neutropenia (fever with an ANC <1000) ( Table 6 ).
Discussion
This Phase II study was conducted to evaluate the ability of dasatinib to produce sustained hematologic and cytogenetic responses in patients with imatinib-resistant/-intolerant CML-AP.
The results presented here with relatively short follow-up show that dasatinib induced an overall hematologic response in 81% of patients, including 64% with a MaHR. In addition, a MCyR was achieved by 33% of patients, including 24% who achieved a CCyR. Importantly, only seven of the 69 patients who achieved a MaHR had progressed at 8 months'. Seventy-six percent of patients in the total treated population are estimated to be alive and progression-free at 10 months. Overall, dasatinib response rates were comparable between imatinib-resistant and -intolerant subgroups.
It is important to put these results in the context of the extent to which patients in this study population had been pre-treated. The median time from original diagnosis of CML to study entry was over 5.5 years, and patients had been heavily pre-treated with imatinib and other therapies.
For patients with CML-AP that is imatinib-resistant or -intolerant, as in this study, there are few effective therapeutic options currently available. Imatinib resistance is particularly problematic in advanced CML, since the incidence of both primary and acquired resistance are greater in the accelerated and blast phases compared with chronic phase 11, 34 . One possible explanation for this is the involvement of pathways involving SFKs in the progression of the disease. Preclinical studies in mice have shown that SFKs are required for the induction of an acute leukemia phenotype but are not required to induce a model of chronic phase CML, and blocking pathways For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From involving SFKs with dasatinib prevents CML progression from chronic to blast phase 24, 35 . Furthermore, in mice with acute leukemia, targeting BCR-ABL alone with imatinib has little effect, but targeting both BCR-ABL and SFK activity with dasatinib results in a marked prolongation of survival 35 . In light of these preclinical findings, the clinical activity of dasatinib observed in this Phase II study may be partly due to dasatinib's potent inhibition of SFKs. Other possible mechanisms of imatinib resistance include amplification of the BCR-ABL gene 17, 18 , and overexpression of the P-glycoprotein efflux pump, for which imatinib -but not dasatinib -is a substrate 19, 20 .
Dasatinib's ability to overcome these forms of resistance may also account for the efficacy seen in this study.
The best-understood mechanism of imatinib resistance involves mutations in BCR-
ABL that preclude binding of imatinib to the BCR-ABL kinase domain 18 . In this study, 60% of patients had BCR-ABL mutations at baseline. Despite this, response rates to dasatinib in this group were similar to those in the study population as a whole. In addition, comparable response rates to dasatinib were observed in patients with mutations in the BCR-ABL P-loop compared with mutations located elsewhere -a significant finding given that previous studies have shown that P-loop mutations may be associated with a lower life expectancy in patients treated with imatinib 36 . The activity of dasatinib in these patients is likely due to its less stringent binding requirements, as dasatinib has the ability to bind to both active and inactive BCR-ABL conformations 1 . Recent crystal structure studies support this hypothesis, showing a more significant role for the P-loop in imatinib binding compared with dasatinib binding 37 . In confirmation of preclinical findings 1, 28 , the only BCR-ABL mutation resistant to dasatinib in the current study is the ATP binding site mutation T315I. Mutations of this residue, sometimes termed the 'gatekeeper' residue, are relatively uncommon, affecting only 5% of patients in this study, but appear to be For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From critical for binding of all ATP-competitive BCR-ABL kinase inhibitors, since the T315I mutation also prevents the activity of imatinib and nilotinib 1 .
Dasatinib was generally well-tolerated in this study; at 8 months' follow-up, only 6%
of patients in the entire safety population had withdrawn from therapy due to drugrelated toxicities. Non-hematologic AE were mostly mild-to-moderate in intensity, with the most common side effects being GI events (diarrhea, nausea, vomiting, abdominal pain and GI bleeding), headache, pyrexia, fatigue and peripheral edema.
Among the subset of patients who experienced episodes of pleural effusion while on dasatinib therapy, temporary dose interruption as well as diuretic and/or pulse steroid therapy typically led to resolution of these events. Resumption of dasatinib at a lower dose enabled most patients to continue treatment without recurrence of the complication.
Of the 8 patients in the treated population who had imatinib-intolerant disease, 2 had discontinued dasatinib treatment at 8 months' follow-up, but neither instance was due to dasatinib-related toxicity. These findings suggest minimal cross-intolerance between dasatinib and imatinib.
Given the paucity of normal blood cell progenitors in patients in this phase of CML, the observed frequency of cytopenia may reflect the potent activity of dasatinib against leukemic cells. Despite the relatively frequent occurrence of rapid-onset and severe neutropenia, no patients had discontinued therapy due to infection related to dasatinib therapy by the time of this analysis. Nevertheless, it will be important to carefully monitor patients for complications related to cytopenia, as is the case with most forms of treatment for advanced-phase CML 38, 39 . As would be expected for heavily pre-treated patients with accelerated phase disease, many patients on this (17) 5 (5) 16 (16) 5 (5) 2 ( 
